Immatics And Roche Sign Cancer Vaccine And Immunotherapy Collaboration
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For additional information on immatics please visit http://www.immatics.com or contact:
Paul Higham, CEO Dr. Nikola Wiegeler, Assistant to the Management immatics biotechnologies GmbH Phone: +49-7071-5397-110 E-mail: firstname.lastname@example.org Citigate Dewe Rogerson David Dible / Chris Gardner / Sita Shah Phone: +44-207-638-9571 E-mail: email@example.com For additional information on Roche please visit http://www.roche.com or contact: Diana Gibson Roche Partnering Communications E-mail: firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts